Show simple item record

dc.contributor.authorMarchbank, T
dc.contributor.authorLimdi, JK
dc.contributor.authorMahmood, A
dc.contributor.authorElia, G
dc.contributor.authorPlayford, RJ
dc.date.accessioned2010-05-25T14:49:59Z
dc.date.available15-09-2008
dc.date.available2010-05-25T14:49:59Z
dc.date.issued2010-05-25T14:49:59Z
dc.identifier.issn0269-2813
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/164
dc.description.abstractBackground A partially hydrolysed and dried product of pacific whiting fish is marketed as a health food supplement supporting 'intestinal health'.Aim To examine whether the partially hydrolysed and dried product of pacific whiting fish influenced the small intestinal damaging side effects of the nonsteroidal anti-inflammatory drug, indomethacin.Methods Eight human volunteers completed a double-blind, placebo-controlled, crossover protocol of clinically relevant dose of indomethacin (50 mg t.d.s. p.o. for 5 days) with 7 days of fish hydrolysate or placebo starting 2 days prior to indomethacin. Changes in gut permeability were assessed using 5 h urinary lactulose:rhamnose (L/R) ratios.Results Fish hydrolysate given alone did not affect permeability. In the main study (n = 8), baseline values were similar for both arms (0.28 +/- 0.05 and 0.35 +/- 0.07). Administration of indomethacin (+placebo) caused a fivefold rise in L/R ratios (increasing to 1.54 +/- 0.35), whereas L/R ratios in the same subjects ingesting indomethacin + fish hydrolysate was only 0.59 +/- 0.14 (P < 0.01 vs. indomethacin alone). Dyspeptic symptoms occurred in four of eight subjects taking indomethacin alone, but zero of eight when hydrolysate was co-administered.Conclusion Natural bioactive products (nutriceuticals), such as fish hydrolysates, may provide a novel approach to the prevention and treatment of NSAID-induced and other gastrointestinal injurious conditions.
dc.format.extent799 - 804
dc.languageEN
dc.publisherBLACKWELL PUBLISHING
dc.relation.isreplacedby123456789/178
dc.relation.isreplacedbyhttps://qmro.qmul.ac.uk/jspui/handle/123456789/164
dc.subjectNONSTEROIDAL ANTIINFLAMMATORY DRUGS
dc.subjectHEALTH FOOD SUPPLEMENT
dc.subjectPERMEABILITY
dc.subjectDAMAGE
dc.subjectGUT
dc.subjectN-3
dc.titleClinical trial: protective effect of a commercial fish protein hydrolysate against indomethacin (NSAID)-induced small intestinal injury
dc.identifier.doi10.1111/j.1365-2036.2008.03783.x
pubs.issue6
pubs.volume28


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record